MAPK

[Nanotechnology] Selenium nanoparticles could competitively inhibit the binding of bFGF to fibroblast growth factor receptor through direct binding to bFGF, down-regulate the expression of bFGF in HUVEC cells, and significantly reduce the MAPK/Erk and P13K/AKT pathways activation of signaling molecules to regulate HUVEC cell migration and angiogenesis.

[Translational Oncology] Experiments in a mouse xenograft model using allo lymphocytes showed that PTPN3 inhibition in small cell lung cancer cells enhanced the anti-tumor effect of phosphatase non-receptor type 3 (PTPN3)-suppressed activated lymphocytes.

[Signal Transduction and Targeted Therapy] Aberrant bone marrow-M1/M2 MФ polarization, characterized by increased M1 MФs and decreased M2 MФs and accompanied by impaired megakaryopoiesis-supporting abilities, was found in patients with thrombocytopenia post-allotransplant.

[Scientific Reports] Scientists found that acrolein induced oncogenic transformation, including faster cell cycling, proliferation, sphere formation and cell migration, in fibroblast cells, and acrolein-induced DNA damages were higher in colorectal cancer (CRC) tumor tissues than in normal epithelial cells in CRC patients.

[Scientific Reports] Examining human specimens from free myocutaneous flap transfer demonstrated increased myostatin signaling and tissue damage in terms of apoptotic activity, cell death, tissue edema, and lipid peroxidation.

[Cancer Gene Therapy] The authors reported that cabozantinib could promote differentiation in erythroid leukemia cells and found that K562 erythroid leukemia cells treated with 1 μM cabozantinib for 72 hours underwent erythroid lineage differentiation.